Navigation Links
Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer
Date:11/3/2009

CHICAGO - Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results, opening the door to larger scale investigation, according to new research from The University of Texas M. D. Anderson Cancer Center.

The Phase II study was presented today (Nov. 3) in an oral session at the annual meeting of the American Society for Radiation Oncology (ASTRO), by Ritsuko Komaki, M.D., professor and program director of Lung Cancer Research and Thoracic Radiation Oncology, Department of Radiation Oncology at M. D. Anderson.

"While still early, these may be the most important study findings for limited stage small cell lung cancer in the past decade," said Komaki, the study's lead author. "This research is important because it achieved a high level of control of the disease while minimizing damage to the esophagus."

Treatment can be problematic

According to the American Cancer Society, lung cancer is the leading cause of cancer death for men and women in this country. Almost 220,000 cases will be diagnosed in 2009, and more than 159,000 people will die of the disease.

Small cell lung cancer is an aggressive cancer that accounts for about 20 percent of lung cancers; approximately 20 percent of these cases are classified as LSCL, defined as cancer present in one lung and possible lymph node involvement, but has not metastasized.

"Over the past few years, we have made significant progress by giving concurrent chemotherapy and thoracic radiotherapy (radiation to the chest), as well as prophylactic cranial radiotherapy (radiation to the head to prevent cancer)," said Komaki, who also holds the Gloria Lupton Tennison Distinguished Professorship in Lung Cancer Research at M. D. Anderson. "However, five-year survival in limited stage small cell lung cancer is still only 26 percent, and the likelihood of recurrence and metastasis is still too high."

A previous phase III study conducted at M. D. Anderson and other sites through the North America Intergroup, showed accelerated fractionated radiotherapy (treatment in which radiation levels are increased over time) with concurrent VP-16 (etoposide) and cisplatin (platinum-based drugs) improved five-year survival rates. But this treatment often causes other side effects.

"Severe inflammation of the lining of the esophagus, also known as acute esophagitis, is a significant risk in this type of treatment," Komaki said. "Therefore, despite its long-term survival benefit, this modality has not been popular in community hospitals."

"Boosts" increase radiation levels

Researchers at M. D. Anderson and their colleagues developed this new study to find a way to increase the level of radiation during concurrent chemotherapy without increasing damage to normal tissue. Supported by NCI grant, this clinical study was then proposed to the Radiation Therapy Oncology Group (RTOG).

Patients with LSCL were treated with thoracic radiotherapy that was accelerated slowly over three weeks. The next step included two weeks of higher radiation levels twice daily, for a total of five weeks. During radiotherapy, patients received four cycles of chemotherapy.

"We gave the patients boosts of radiation twice a day in the last two weeks of treatment, when resistant cells often start to proliferate," Komaki said.

During the median follow-up time of 19 months, 41 percent of patients experienced complete response, and another 39 percent had partial response. Despite the higher radiation dose, the rate of acute severe esophagitis was significantly lower than the previous study, 18 percent, vs. 27 percent, respectively.

However, at 36.6 percent, the two-year survival rate did not improve. In addition, while local control of the disease was excellent, 80 percent, the majority of patients still developed distant metastasis, Komaki said.

Further study is planned

Komaki said further study is needed, possibly including a cycle of induction chemotherapy before concurrent treatment. Improved systemic treatment and staging work-ups are needed too, she said.

This study has been adapted by a new randomized intergroup trial (CALGB/RTOG/ECOG/SWOG) that will enroll 700 patients in multiple sites across the country. This research will compare three radiation dose levels and treatment duration times.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. New national study finds increasing number of injuries from hot tubs
2. CDC Study Links 2 Antibiotics to Birth Defects
3. Fred Hutchinson Cancer Research Center Seeks Seattle Area Volunteers for a Stress-reduction Study
4. Study reveals second pathway to feeling your heartbeat
5. New Study Finds Shock-Wave Therapy for Unhealed Fractured Bones as Effective as Surgery
6. AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
7. Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting
8. Study spotlights efficacy of questionnaire to identify patients at high risk for lung cancer
9. Study shows that sleep deprivation can negatively affect information processing
10. Study shows that sleep disturbances improve after retirement
11. Henry Ford Hospital study: A MRSA strain linked to high death rates
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology: